10,244 Shares in Terns Pharmaceuticals, Inc. $TERN Purchased by Tema Etfs LLC

Tema Etfs LLC acquired a new position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,244 shares of the company’s stock, valued at approximately $414,000.

A number of other large investors also recently added to or reduced their stakes in TERN. Commodore Capital LP bought a new position in shares of Terns Pharmaceuticals in the 3rd quarter valued at about $42,807,000. Vanguard Group Inc. raised its stake in shares of Terns Pharmaceuticals by 5.9% during the third quarter. Vanguard Group Inc. now owns 4,559,917 shares of the company’s stock worth $34,245,000 after buying an additional 253,751 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Terns Pharmaceuticals by 3.8% during the second quarter. Geode Capital Management LLC now owns 1,633,349 shares of the company’s stock worth $6,094,000 after buying an additional 59,145 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in Terns Pharmaceuticals in the second quarter valued at approximately $4,774,000. Finally, Integral Health Asset Management LLC boosted its stake in Terns Pharmaceuticals by 35.7% in the third quarter. Integral Health Asset Management LLC now owns 950,000 shares of the company’s stock valued at $7,134,000 after acquiring an additional 250,000 shares during the last quarter. 98.26% of the stock is currently owned by institutional investors and hedge funds.

Terns Pharmaceuticals Trading Down 0.1%

TERN opened at $52.72 on Friday. The stock has a market capitalization of $6.08 billion, a P/E ratio of -51.18 and a beta of -0.37. Terns Pharmaceuticals, Inc. has a 12 month low of $1.87 and a 12 month high of $53.19. The firm’s fifty day simple moving average is $42.59 and its 200 day simple moving average is $30.32.

Terns Pharmaceuticals (NASDAQ:TERN) last released its earnings results on Thursday, April 2nd. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.06. On average, equities research analysts predict that Terns Pharmaceuticals, Inc. will post -1.19 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TERN has been the subject of a number of analyst reports. Truist Financial lowered shares of Terns Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their target price for the stock from $56.00 to $53.00 in a report on Tuesday. Jefferies Financial Group restated a “buy” rating and issued a $70.00 price target on shares of Terns Pharmaceuticals in a research report on Wednesday, December 10th. Barclays reaffirmed an “equal weight” rating and set a $53.00 price objective (down from $56.00) on shares of Terns Pharmaceuticals in a research note on Monday. Oppenheimer upped their price objective on Terns Pharmaceuticals from $28.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. Finally, Leerink Partners assumed coverage on Terns Pharmaceuticals in a report on Monday, February 9th. They set an “outperform” rating and a $58.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $56.30.

Insider Activity

In other Terns Pharmaceuticals news, CEO Amy L. Burroughs sold 71,339 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $38.10, for a total value of $2,718,015.90. Following the sale, the chief executive officer owned 138,976 shares in the company, valued at approximately $5,294,985.60. The trade was a 33.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Emil Kuriakose sold 942 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $52.75, for a total value of $49,690.50. Following the transaction, the insider directly owned 105,673 shares of the company’s stock, valued at approximately $5,574,250.75. This trade represents a 0.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 170,196 shares of company stock valued at $6,568,912 over the last ninety days. 1.50% of the stock is owned by insiders.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.